About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a publicly listed company based in United States founded in 1995. Small molecule drugs for various therapeutic areas are developed. Lexicon Pharmaceuticals has raised $165 million across 13 funding rounds from investors including NEA, Bay City Capital and Military Health. The company has 103 employees. Lexicon Pharmaceuticals offers products and services including Gene-based Therapies. Its focus areas include Life Sciences, Genomics, Genomics Research and Biomarker Discovery. Its legal entity is Lexicon Pharmaceuticals, Inc. Its competitors include Metabolon, Kriya Therapeutics and Sana Biotechnology; 3 of its 3 listed competitors have raised funding.
Company details
Lexicon Pharmaceuticals was founded in 1995 in the United States as a biopharmaceutical company. Gene trapping and targeting technologies are utilized to identify drug targets and create small molecule drugs. Focus areas include oncology, gastroenterology, immunology, metabolism, and ophthalmology. Operations center on research and development within the healthcare sector, with activities based primarily in the U.S.
- Headquarters United States
- Employees 103
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website lexpharma.com
- Social LinkedIn X
- Legal Name Lexicon Pharmaceuticals, Inc.
- Annual Revenue$49.8 M (USD)60.24as on Dec 31, 2025
- Net Profit-$50.34 M (USD)74.88as on Dec 31, 2025
- EBITDA-$48.29 M (USD)73.8as on Dec 31, 2025
- Total Equity Funding$165M (USD)
in 13 rounds
- Latest Funding Round$55.67M (USD), Post-IPO
Feb 2026
- InvestorsNEA
& 2 more
- Employee Count103
Products & Services of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals offers a comprehensive portfolio of products and services, including Gene-based Therapies.
Develops medicines targeting neuropathic pain and cardiometabolic disorders using gene science.
Funding Insights of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals has successfully raised a total of $165M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $55.67 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $165M
- Total Rounds 13
- Last Round Post-IPO — $55.67M
- Investors Count 3
Latest 10 of 13 funding rounds of Lexicon Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $55.67M | Post-IPO | – | – | – |
| Aug 2022 | $42.89M | Post-IPO | – | – | – |
| Mar 2017 | $10.51M | Post-IPO | – | – | – |
| Dec 2014 | $4.66M | Post-IPO | – | – | – |
| Dec 2014 | $150M | Post-IPO | – | – | – |
| Nov 2014 | $130M | Private Equity Round | – | – | – |
| Aug 2012 | $35M | Private Equity Round | – | – | – |
| Jul 2012 | $35M | Post-IPO | – | – | – |
| Mar 2010 | $75.04M | Post-IPO | – | – | – |
| Jun 2008 | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Lexicon Pharmaceuticals
Lexicon Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include NEA, Bay City Capital and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Lexicon Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lexicon Pharmaceuticals
45 people are tracked at Lexicon Pharmaceuticals (25 in leadership, 20 in team); the tracked headcount is 103.
| Name | Role | Group |
|---|---|---|
Ivan Cheung | Board of Directors | Leadership |
Ray Debbane | Chairman of Board | Leadership |
Lonnel Coats | CEO & Director | Leadership |
Darren Orton | Director Of Medicinal Chemistry | Leadership |
Nandkumar Bhogle | Director, Chemical Development | Leadership |
Wendy E. Mcdermott | Vice President, Human Resources | Leadership |
Kristen L. Alexander | Vice President, Finance and Accounting | Leadership |
Craig B. Granowitz | SVP & Chief Medical Officer | Leadership |
Annie Bellamy | Associate Director, Payroll | Leadership |
Chan Li | Director Of Analytical Development | Leadership |
Steven Brown | Senior Director, Accounting & Finance | Leadership |
Godfried Owusu-Ababio | Vice President, Technical Operations | Leadership |
Matthew Zhao | Executive Director, API Development And Manufacture | Leadership |
Alan G.e. Wilson | VP | Leadership |
Polina Binder | Sr. Director, Pharmacovigilance & Drug Safety | Leadership |
Belinda Hardin | Senior Director | Leadership |
Kartik Patel | Associate Director, Drug Safety Operations | Leadership |
Nicole Moore | Vice President Legal | Leadership |
Mary McKinney | Executive Director Of Human Resources | Leadership |
Saturday Siekman | Executive Director, Human Resources & Head Of Total Rewards | Leadership |
25 more people are available in the full profile.
Complete people profiles for Lexicon Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol LXRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Apr 2000
- Listed onNASDAQ: LXRX
- Listed entityLexicon Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS5288723027
- Share price$1.61 (-2.42% on the day) · 2026-10-13
- Market capitalisation$716.4M
- EPS (diluted, trailing year)$-0.15
- Volume (last session)2,051,211
Financials of Lexicon Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $49.8M | -$50.3M | -$48.3M |
| 2024 | $31.1M | -$200.4M | -$184.3M |
| 2023 | $1.2M | -$177.1M | -$171.2M |
| 2022 | $139,000 | -$101.9M | -$100.3M |
| 2021 | $298,000 | -$87.8M | -$86.8M |
Detailed financial statements for Lexicon Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Lexicon Pharmaceuticals
4 dated milestones of Lexicon Pharmaceuticals across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Lexicon Pharmaceuticals is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $55.7M.
Competitors of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Metabolon, Kriya Therapeutics and Sana Biotechnology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. |
Detailed competitors of Lexicon Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lexicon Pharmaceuticals
The website of Lexicon Pharmaceuticals (lexpharma.com) receives about 9.1K visits a month and ranks #2,526,903 among all websites worldwide, #3,471 in Biotechnology and Pharmaceuticals.
- Monthly visits9.1K
▲ 8.5% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,526,903
among all websites
- Category rank#3,471
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.9
- Average visit31 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Lexicon Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
us.astellas.com | us.astellas.com | 100% | – | ||
| westpharma.com | 93% | 101.1K | #397,912 | View details | |
| hgsi.com | 90% | View details | |||
lexpharmacareers.silkroad.com | lexpharmacareers.silkroad.com | 90% | – | ||
| citeline.com | 88% | 127.1K | #291,889 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Lexicon Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Lexicon Pharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lexicon Pharmaceuticals
Complete news archive for Lexicon Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lexicon Pharmaceuticals
Lexicon Pharmaceuticals was founded in 1995 and raised its 1st funding round 3 years after it was founded.
Lexicon Pharmaceuticals is headquartered in United States.
Lexicon Pharmaceuticals is a funded company, having raised a total of $165M across 13 funding rounds to date.
Lexicon Pharmaceuticals has 103 employees.
Annual revenue of Lexicon Pharmaceuticals is $49.8M as on Dec 31, 2025.
Lexicon Pharmaceuticals was founded in 1995 in the United States as a biopharmaceutical company. Gene trapping and targeting technologies are utilized to identify drug targets and create small molecule drugs. Focus areas include oncology, gastroenterology, immunology, metabolism, and ophthalmology. Operations center on research and development within the healthcare sector, with activities based primarily in the U.S.
Lexicon Pharmaceuticals's top competitors include Metabolon, Sana Biotechnology and Kriya Therapeutics.
Lexicon Pharmaceuticals offers Gene-based Therapies.
Yes, Lexicon Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol LXRX.
Lexicon Pharmaceuticals has 3 investors. Key investors include NEA, Bay City Capital, and Military Health.
Lexicon Pharmaceuticals operates through Lexicon Pharmaceuticals, Inc..